Decreased Semaphorin3A expression correlates with disease activity and histological features of rheumatoid arthritis

BMC Musculoskeletal Disorders

Tomoyuki Saito³  Yoshio Goshima²  Yoji Nagashima¹  Ken Kumagai³  Fumio Nakamura²  Shu Takagawa³ 

[1] Department of Molecular Pathology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan;Department of Molecular Pharmacology and Neurobiology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan;Department of Orthopaedic Surgery, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan

关键词: Histological scoring;    Disease activity score;    Semaphorin3A;    Rheumatoid arthritis;   

Others  :  1134099
DOI  :  10.1186/1471-2474-14-40

 received in 2012-09-10, accepted in 2013-01-12,  发布年份 2013

【 摘 要 】

Background

Rheumatoid arthritis (RA) is an autoimmune disease of which the pathogenetic mechanisms are not fully understood. Semaphorin3A (Sema3A) has an immune regulatory role. Neuropilin1 (NRP1), the primary receptor for Sema3A, is also a receptor for vascular endothelial growth factor 165 (VEGF₁₆₅). It has been shown that Sema3A competitively antagonizes VEGF165 signaling. This study investigated whether Sema3A is expressed in synovial tissues, and is associated with disease activity and the histological features of synovial tissues from RA patients.

Methods

Human synovial tissues samples were obtained from RA and osteoarthritis (OA) patients. Disease activity of RA patients was calculated using the 28-joint Disease Activity Score based on C-reactive protein (DAS28-CRP). The histological features of RA synovial tissues were evaluated using Rooney’s inflammation scoring system. The localization of Sema3A, VEGF₁₆₅ and NRP1 positive cells was immunohistochemically determined in synovial tissues. Expression levels of Sema3A, VEGF-A and NRP1 mRNA were determined using quantitative real-time polymerase chain reaction (qPCR).

Results

In OA specimens, Sema3A, VEGF₁₆₅ and NRP1 proteins were expressed in the synovial lining and inflammatory cells beneath the lining. Immunohistochemistry revealed the protein expression of Sema3A in synovial lining cells was decreased in RA tissues compared with OA samples. qPCR analysis demonstrated a significant reduction of Sema3A mRNA levels in RA synovial tissue samples than in OA and a significant correlation of the ratio of Sema3A/VEGF-A mRNA expression levels with DAS28-CRP (R = −0.449, p = 0.013). Sema3A mRNA levels also correlated with Rooney’s inflammation score, especially in perivascular infiltrates of lymphocytes (R = −0.506, p = 0.004), focal aggregates of lymphocytes (R = −0.501, p = 0.005) and diffuse infiltrates of lymphocytes (R = −0.536, p = 0.002).

Conclusions

Reduction of Sema3A expression in RA synovial tissues may contribute to pathogenesis of RA.

【 授权许可】

   
2013 Takagawa et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Nagaoka A, Takizawa N, Takeuchi R, Inaba Y, Saito I, Nagashima Y, Saito T, Aoki I: Possible involvement of peptidylprolyl isomerase Pin1 in rheumatoid arthritis. Pathol Int 2011, 61(2):59-66.
• [2]Matsuo K, Arito M, Noyori K, Nakamura H, Kurokawa MS, Masuko K, Okamoto K, Nagai K, Suematsu N, Yudoh K, et al.: Arthritogenicity of annexin VII revealed by phosphoproteomics of rheumatoid synoviocytes. Ann Rheum Dis 2011, 70(8):1489-1495.
• [3]Neumann E, Lefevre S, Zimmermann B, Gay S, Muller-Ladner U: Rheumatoid arthritis progression mediated by activated synovial fibroblasts. Trends Mol Med 2010, 16(10):458-468.
• [4]McInnes IB, Schett G: Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007, 7(6):429-442.
• [5]Yazdani U, Terman JR: The semaphorins. Genome Biol 2006, 7(3):211. BioMed Central Full Text
• [6]Fassold A, Falk W, Anders S, Hirsch T, Mirsky VM, Straub RH: Soluble neuropilin-2, a nerve repellent receptor, is increased in rheumatoid arthritis synovium and aggravates sympathetic fiber repulsion and arthritis. Arthritis Rheum 2009, 60(10):2892-2901.
• [7]Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD: Neuropilin is a semaphorin III receptor. Cell 1997, 90(4):753-762.
• [8]Gaur P, Bielenberg DR, Samuel S, Bose D, Zhou Y, Gray MJ, Dallas NA, Fan F, Xia L, Lu J, et al.: Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis. Clin Cancer Res 2009, 15(22):6763-6770.
• [9]Lepelletier Y, Moura IC, Hadj-Slimane R, Renand A, Fiorentino S, Baude C, Shirvan A, Barzilai A, Hermine O: Immunosuppressive role of semaphorin-3A on T cell proliferation is mediated by inhibition of actin cytoskeleton reorganization. Eur J Immunol 2006, 36(7):1782-1793.
• [10]Kurschat P, Bielenberg D, Rossignol-Tallandier M, Stahl A, Klagsbrun M: Neuron restrictive silencer factor NRSF/REST is a transcriptional repressor of neuropilin-1 and diminishes the ability of semaphorin 3A to inhibit keratinocyte migration. J Biol Chem 2006, 281(5):2721-2729.
• [11]Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagsbrun M: Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 1999, 146(1):233-242.
• [12]Takamatsu H, Takegahara N, Nakagawa Y, Tomura M, Taniguchi M, Friedel RH, Rayburn H, Tessier-Lavigne M, Yoshida Y, Okuno T, et al.: Semaphorins guide the entry of dendritic cells into the lymphatics by activating myosin II. Nat Immunol 2010, 11(7):594-600.
• [13]Vadasz Z, Haj T, Halasz K, Rosner I, Slobodin G, Attias D, Kessel A, Kessler O, Neufeld G, Toubi E: Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus. Arthritis Res Ther 2012, 14(3):R146. BioMed Central Full Text
• [14]Catalano A: The neuroimmune semaphorin-3A reduces inflammation and progression of experimental autoimmune arthritis. J Immunol 2010, 185(10):6373-6383.
• [15]Goshima Y, Ito T, Sasaki Y, Nakamura F: Semaphorins as signals for cell repulsion and invasion. J Clin Invest 2002, 109(8):993-998.
• [16]Takahashi T, Fournier A, Nakamura F, Wang LH, Murakami Y, Kalb RG, Fujisawa H, Strittmatter SM: Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. Cell 1999, 99(1):59-69.
• [17]Sasaki Y, Cheng C, Uchida Y, Nakajima O, Ohshima T, Yagi T, Taniguchi M, Nakayama T, Kishida R, Kudo Y, et al.: Fyn and Cdk5 mediate semaphorin-3A signaling, which is involved in regulation of dendrite orientation in cerebral cortex. Neuron 2002, 35(5):907-920.
• [18]Walmsley MJ, Ooi SK, Reynolds LF, Smith SH, Ruf S, Mathiot A, Vanes L, Williams DA, Cancro MP, Tybulewicz VL: Critical roles for Rac1 and Rac2 GTPases in B cell development and signaling. Science 2003, 302(5644):459-462.
• [19]Benvenuti F, Hugues S, Walmsley M, Ruf S, Fetler L, Popoff M, Tybulewicz VL, Amigorena S: Requirement of Rac1 and Rac2 expression by mature dendritic cells for T cell priming. Science 2004, 305(5687):1150-1153.
• [20]Bruder D, Probst-Kepper M, Westendorf AM, Geffers R, Beissert S, Loser K, von Boehmer H, Buer J, Hansen W: Neuropilin-1: a surface marker of regulatory T cells. Eur J Immunol 2004, 34(3):623-630.
• [21]Kawamura H, Li X, Goishi K, van Meeteren LA, Jakobsson L, Cebe-Suarez S, Shimizu A, Edholm D, Ballmer-Hofer K, Kjellen L, et al.: Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. Blood 2008, 112(9):3638-3649.
• [22]Nakamura F, Kalb RG, Strittmatter SM: Molecular basis of semaphorin-mediated axon guidance. J Neurobiol 2000, 44(2):219-229.
• [23]Vadasz Z, Attias D, Kessel A, Toubi E: Neuropilins and semaphorins - from angiogenesis to autoimmunity. Autoimmun Rev 2010, 9(12):825-829.
• [24]Kurosaka D, Hirai K, Nishioka M, Miyamoto Y, Yoshida K, Noda K, Ukichi T, Yanagimachi M, Furuya K, Takahashi E, et al.: Clinical significance of serum levels of vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in patients with rheumatoid arthritis. J Rheumatol 2010, 37(6):1121-1128.
• [25]Clavel G, Bessis N, Lemeiter D, Fardellone P, Mejjad O, Menard JF, Pouplin S, Boumier P, Vittecoq O, Le Loet X, et al.: Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin Immunol 2007, 124(2):158-164.
• [26]Kigel B, Varshavsky A, Kessler O, Neufeld G: Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells. PLoS One 2008, 3(9):e3287.
• [27]Barresi V, Tuccari G: Increased ratio of vascular endothelial growth factor to semaphorin3A is a negative prognostic factor in human meningiomas. Neuropathology 2010, 30(5):537-546.
• [28]Osada R, Horiuchi A, Kikuchi N, Ohira S, Ota M, Katsuyama Y, Konishi I: Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas. Hum Pathol 2006, 37(11):1414-1425.
• [29]Bachelder RE, Lipscomb EA, Lin X, Wendt MA, Chadborn NH, Eickholt BJ, Mercurio AM: Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer Res 2003, 63(17):5230-5233.
• [30]Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al.: The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31(3):315-324.
• [31]Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, et al.: Development of criteria for the classification and reporting of osteoarthritisl. Classification of osteoarthritis of the knee. Diagnostic and therapeutic criteria committee of the American rheumatism association. Arthritis Rheum 1986, 29(8):1039-1049.
• [32]Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N: Comparison of disease activity score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis 2007, 66(3):407-409.
• [33]Rooney M, Condell D, Quinlan W, Daly L, Whelan A, Feighery C, Bresnihan B: Analysis of the Histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum 1988, 31(8):956-963.
• [34]Kou K, Nakamura F, Aihara M, Chen H, Seto K, Komori-Yamaguchi J, Kambara T, Nagashima Y, Goshima Y, Ikezawa Z: Decreased expression of semaphorin-3A, a neurite-collapsing factor, is associated with itch in psoriatic skin. Acta Derm Venereol 2012, 92(5):521-528.
• [35]Takemura S, Braun A, Crowson C, Kurtin PJ, Cofield RH, O'Fallon WM, Goronzy JJ, Weyand CM: Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001, 167(2):1072-1080.
• [36]Sakurai N, Kuroiwa T, Ikeuchi H, Hiramatsu N, Maeshima A, Kaneko Y, Hiromura K, Nojima Y: Expression of IL-19 and its receptors in RA: potential role for synovial hyperplasia formation. Rheumatology (Oxford) 2008, 47(6):815-820.
• [37]Kumanogoh A, Kikutani H: Semaphorins and their receptors: novel features of neural guidance molecules. Proc Jpn Acad Ser B Phys Biol Sci 2010, 86(6):611-620.
• [38]Tominaga M, Ogawa H, Takamori K: Decreased production of semaphorin 3A in the lesional skin of atopic dermatitis. Br J Dermatol 2008, 158(4):842-844.
• [39]Takamatsu H, Okuno T, Kumanogoh A: Regulation of immune cell responses by semaphorins and their receptors. Cell Mol Immunol 2010, 7(2):83-88.
• [40]Sarris M, Andersen KG, Randow F, Mayr L, Betz AG: Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity 2008, 28(3):402-413.
• [41]Boissier MC, Assier E, Biton J, Denys A, Falgarone G, Bessis N: Regulatory T cells (Treg) in rheumatoid arthritis. Joint Bone Spine 2009, 76(1):10-14.
• [42]Neufeld G, Kessler O: The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer 2008, 8(8):632-645.
• [43]Fukamachi S, Bito T, Shiraishi N, Kobayashi M, Kabashima K, Nakamura M, Tokura Y: Modulation of semaphorin 3A expression by calcium concentration and histamine in human keratinocytes and fibroblasts. J Dermatol Sci 2011, 61(2):118-123.
• [44]Adlesic M, Verdrengh M, Bokarewa M, Dahlberg L, Foster SJ, Tarkowski A: Histamine in rheumatoid arthritis. Scand J Immunol 2007, 65(6):530-537.
• [45]Tanaka S, Sohen S, Fukuda K: A role for histamine receptors in rheumatoid arthritis. Semin Arthritis Rheum 1997, 26(6):824-833.
• [46]Hashimoto A, Tarner IH, Bohle RM, Gaumann A, Manetti M, Distler O, Steinmeyer J, Ulfgren AK, Schulz A, Gay S, et al.: Analysis of vascular gene expression in arthritic synovium by laser-mediated microdissection. Arthritis Rheum 2007, 56(4):1094-1105.
• [47]Lowin T, Weidler C, Jenei-Lanzl Z, Capellino S, Baerwald CG, Buttgereit F, Straub RH: Relationship between placenta growth factor 1 and vascularization, dehydroepiandrosterone sulfate to dehydroepiandrosterone conversion, or aromatase expression in patients with rheumatoid arthritis and patients with osteoarthritis. Arthritis Rheum 2012, 64(6):1799-1808.
• [48]Lee SS, Joo YS, Kim WU, Min DJ, Min JK, Park SH, Cho CS, Kim HY: Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 2001, 19(3):321-324.
• [49]Ikeda M, Hosoda Y, Hirose S, Okada Y, Ikeda E: Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. J Pathol 2000, 191(4):426-433.
• [50]Kim WU, Kang SS, Yoo SA, Hong KH, Bae DG, Lee MS, Hong SW, Chae CB, Cho CS: Interaction of vascular endothelial growth factor 165 with neuropilin-1 protects rheumatoid synoviocytes from apoptotic death by regulating Bcl-2 expression and Bax translocation. J Immunol 2006, 177(8):5727-5735.
• [51]Acevedo LM, Barillas S, Weis SM, Gothert JR, Cheresh DA: Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood 2008, 111(5):2674-2680.
• [52]Koch AE: Review: angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum 1998, 41(6):951-962.
• [53]Kong J-S, Yoo S-A, Kim J-W, Yang S-P, Chae C-B, Tarallo V, Falco SD, Ryu S-H, Cho C-S, Kim W-U: Antiâ “neuropilin-1 peptide inhibition of synoviocyte survival, angiogenesis, and experimental arthritis. Arthritis Rheum 2010, 62(1):179-190.
• [54]Yoo SA, Bae DG, Ryoo JW, Kim HR, Park GS, Cho CS, Chae CB, Kim WU: Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes. J Immunol 2005, 174(9):5846-5855.
• [55]Miller LE, Weidler C, Falk W, Angele P, Schaumburger J, Schlmerich J, Straub RH: Increased prevalence of semaphorin 3C, a repellent of sympathetic nerve fibers, in the synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 2004, 50(4):1156-1163.
• [56]Weidler C, Holzer C, Harbuz M, Hofbauer R, Angele P, Scholmerich J, Straub RH: Low density of sympathetic nerve fibres and increased density of brain derived neurotrophic factor positive cells in RA synovium. Ann Rheum Dis 2005, 64(1):13-20.